NAV

Aprindine

Identification

Generic Name
Aprindine
DrugBank Accession Number
DB01429
Background

Aprindine is a cardiac depressant used in arrhythmias.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 322.487
Monoisotopic: 322.24089897
Chemical Formula
C22H30N2
Synonyms
  • Aprindina
  • Aprindine
  • Aprindinum
External IDs
  • AC 1802
  • Compound 99170
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ASodium channel protein type 5 subunit alpha
inhibitor
Humans
UCalmodulin
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hover over products below to view reaction partners

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbataceptThe metabolism of Aprindine can be increased when combined with Abatacept.
AbirateroneThe metabolism of Aprindine can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the arrhythmogenic activities of Aprindine.
AcetaminophenThe metabolism of Aprindine can be decreased when combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Aprindine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Aprindine hydrochloridePB5EKT7Q2V33237-74-0KIPFVRHNAAZJOD-UHFFFAOYSA-N
International/Other Brands
Aspenon / Fibocil (Lilly)

Categories

ATC Codes
C01BB04 — Aprindine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Indanes
Sub Class
Not Available
Direct Parent
Indanes
Alternative Parents
Dialkylarylamines / Aniline and substituted anilines / Aralkylamines / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amine / Aniline or substituted anilines / Aralkylamine / Aromatic homopolycyclic compound / Dialkylarylamine / Hydrocarbon derivative / Indane / Monocyclic benzene moiety / Organic nitrogen compound / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
5Y48085P9Q
CAS number
37640-71-4
InChI Key
NZLBHDRPUJLHCE-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
IUPAC Name
N-[3-(diethylamino)propyl]-N-phenyl-2,3-dihydro-1H-inden-2-amine
SMILES
CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1

References

Synthesis Reference

Vanhoof, P. and Clarebout, P.; British Patent 1,321,424; June 27, 1973; assigned to Manufac- ture de Produits Pharmaceutiques A. Christiaens, SA

General References
Not Available
Human Metabolome Database
HMDB0015498
KEGG Drug
D01326
PubChem Compound
2218
PubChem Substance
46505478
ChemSpider
2132
RxNav
1054
ChEBI
135370
ChEMBL
CHEMBL1213033
ZINC
ZINC000001420561
Therapeutic Targets Database
DAP000954
PharmGKB
PA164764496
Wikipedia
Aprindine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120-121 °CVanhoof, P. and Clarebout, P.; British Patent 1,321,424; June 27, 1973; assigned to Manufacture de Produits Pharmaceutiques A. Christiaens, SA
logP4.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00782 mg/mLALOGPS
logP5.58ALOGPS
logP4.99Chemaxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.94Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area6.48 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity105.22 m3·mol-1Chemaxon
Polarizability40.02 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9776
Caco-2 permeable+0.7047
P-glycoprotein substrateSubstrate0.6441
P-glycoprotein inhibitor IInhibitor0.7951
P-glycoprotein inhibitor IIInhibitor0.5188
Renal organic cation transporterInhibitor0.7209
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateInhibitor0.7381
CYP450 2C9 inhibitorNon-inhibitor0.7661
CYP450 2D6 inhibitorInhibitor0.5
CYP450 2C19 inhibitorInhibitor0.5287
CYP450 3A4 inhibitorNon-inhibitor0.7571
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8111
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6834
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.4059 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7928
hERG inhibition (predictor II)Inhibitor0.7202
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a4i-9581000000-398e96ca144138626ef2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0129000000-f73d62c92552ed786f85
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0139000000-9f3c0b244bee5d884455
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ul0-1932000000-a60bac38296d1f45b24d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0600-0897000000-15bf9a0e978a8f0dd656
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-6900000000-12579a9523759ffd0387
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-053r-1950000000-52d487dc3950556ea70c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-198.8257533
predicted
DarkChem Lite v0.1.0
[M-H]-197.7156533
predicted
DarkChem Lite v0.1.0
[M-H]-175.51015
predicted
DeepCCS 1.0 (2019)
[M+H]+199.2420533
predicted
DarkChem Lite v0.1.0
[M+H]+197.2829533
predicted
DarkChem Lite v0.1.0
[M+H]+177.86815
predicted
DeepCCS 1.0 (2019)
[M+Na]+199.4050533
predicted
DarkChem Lite v0.1.0
[M+Na]+197.5284533
predicted
DarkChem Lite v0.1.0
[M+Na]+184.0196
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Sodium channel protein type 5 subunit alpha
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Sato R, Hisatome I, Tanaka Y, Sasaki N, Kotake H, Mashiba H, Katori R: Aprindine blocks the sodium current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):331-6. [Article]
  2. Kamiya K, Kodama I, Toyama J: A combination of inactivated sodium channel blockers causes competitive interaction on dV/dtmax of single ventricular myocytes. Cardiovasc Res. 1991 Jun;25(6):516-22. [Article]
Details2. Calmodulin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Levine SN, Hollier B: Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6. [Article]

Enzymes

Details1. Cytochrome P450 2D6
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Ebner T, Eichelbaum M: The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. Br J Clin Pharmacol. 1993 Apr;35(4):426-30. [Article]

Carriers

Details1. Alpha-1-acid glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Teirlynck O, Belpaire FM, Andreasen F: Binding of aprindine and moxaprindine to human serum, alpha 1-acid glycoprotein and serum of healthy and diseased humans. Eur J Clin Pharmacol. 1982;21(5):427-31. [Article]

Drug created at July 24, 2007 13:04 / Updated at December 02, 2023 06:59